NDA 022437 · Verity
Trelstar
Triptorelin Pamoate · Intramuscular
Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Mar 10, 2010
Approved uses
1
Original approval plus efficacy supplements
Registered trials
246
82 Phase 3, 36 recruiting
FAERS reports
2,599
1,873 serious, 532 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 30, 2026.
TRELSTAR is indicated for the treatment of advanced prostate cancer [ see Clinical Studies (14) ]. TRELSTAR is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer. ( 1 )
Mechanism: Triptorelin is a synthetic decapeptide agonist analog of gonadotropin releasing hormone (GnRH). Comparative in vitro studies showed that triptorelin was 100-fold more active than native GnRH in stimulating luteinizing hormone release from monolayers of dispersed rat pituitary cells in culture and 20-fold more active than native GnRH in displacing 125 I-GnRH from pituitary receptor sites. In animal studies, triptorelin pamoate was found to have 13‑fold higher luteinizing hormone-releasing activity and 21-fold higher follicle-stimulating hormone-releasing activity compared to the native GnRH.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 10, 2010 Original approval · Type 3 - New Dosage Form ReviewOther Important Information from FDALetter
1 products under this application
- TRELSTAR · TRIPTORELIN PAMOATE EQ 22.5MG BASE/VIAL · INJECTABLE, INTRAMUSCULAR · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Triptorelin Pamoate" as an intervention, any sponsor and status, largest first.
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04961996 · 4,170 participants · Start Aug 27, 2021 · Primary completion Aug 8, 2025
Drug: Giredestrant; Physician's Choice of Endocrine Therapy and 1 more · For: Early Breast Cancer
Sites: Daphne, Alabama; Bakersfield, California; Fullerton, California · 621 sites in all
NRG OncologyAcademic, hospital or other
NCT05879926 · 3,960 participants (planned) · Start Oct 18, 2023 · Primary completion Jan 2032
Drug: Ovarian Function Suppression + Aromatase Inhibitor; Adjuvant Chemotherapy + Ovarian Function Suppression · For: Breast Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 1,276 sites in all
- Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast CancerPivotal-lookingCompleted
ETOP IBCSG Partners FoundationResearch network
NCT00066690 · 3,066 participants · Start Dec 17, 2003 · Primary completion May 2014
Drug: Exemestane; Tamoxifen and 1 more · For: Estrogen Receptor Positive Breast Cancer; Progesterone Receptor Positive Tumor; Recurrent Breast Carcinoma and 5 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Scottsdale, Arizona · 500 sites in all
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialPivotal-lookingActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT04513717 · 2,753 participants · Start Jan 21, 2021 · Primary completion Dec 31, 2033
Drug: Apalutamide; Bicalutamide and 8 more · For: Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
Sites: Fairbanks, Alaska; Gilbert, Arizona; Peoria, Arizona · 602 sites in all
- Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast CancerPivotal-lookingCompleted
ETOP IBCSG Partners FoundationResearch network
NCT00066703 · 2,672 participants · Start Nov 3, 2003 · Primary completion Mar 11, 2011
Drug: exemestane; tamoxifen and 1 more · For: Breast Cancer
Sites: Burbank, California; La Jolla, California; Mission Hills, California · 228 sites in all
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialPivotal-lookingActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT05050084 · 2,050 participants (planned) · Start Dec 6, 2021 · Primary completion Nov 11, 2026
Drug: Bicalutamide; Buserelin and 8 more · For: Prostate Adenocarcinoma
Sites: Birmingham, Alabama; Gilbert, Arizona; Peoria, Arizona · 576 sites in all
- The Effectiveness and Safety of the Prolonged Down-regulation Protocol for Controlled Ovarian HyperstimulationPivotal-lookingStatus unknown
Peking University People's HospitalAcademic, hospital or other
NCT03809221 · 1,892 participants (planned) · Start Feb 1, 2019 · Primary completion Sep 1, 2020
Drug: Triptorelin acetate · For: Infertility, Female
- Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate CancerPivotal-lookingStatus unknown
Radiation Therapy Oncology GroupResearch network
NCT00567580 · 1,792 participants · Start Feb 2008 · Primary completion Jul 12, 2018
Drug: AA; LHRH agonist · For: Prostate Cancer
Sites: Birmingham, Alabama; Fairbanks, Alaska; Peoria, Arizona · 460 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death406
- fatigue128
- hot flush127
- inappropriate schedule of product administration110
- off label use107
- asthenia89
- prostatic specific antigen increased89
- malignant neoplasm progression82
- product dose omission issue82
- disease progression78
- terminal state74
- drug ineffective73
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 5 |
| 2006 | 7 |
| 2007 | 16 |
| 2008 | 7 |
| 2009 | 5 |
| 2010 | 19 |
| 2011 | 33 |
| 2012 | 53 |
| 2013 | 28 |
| 2014 | 47 |
| 2015 | 70 |
| 2016 | 57 |
| 2017 | 58 |
| 2018 | 138 |
| 2019 | 157 |
| 2020 | 221 |
| 2021 | 205 |
| 2022 | 251 |
| 2023 | 268 |
| 2024 | 331 |
| 2025 | 383 |
| 2026 | 237 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Trelstar (Triptorelin Pamoate)
2024 spending
$15.3M
Beneficiaries
2,414
6,223 claims
Per beneficiary
$6,352
$2,463.15 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $10,920,256 |
| 2022 | $14,688,634 |
| 2023 | $14,231,107 |
| 2024 | $15,333,167 |
Part B: Trelstar (Triptorelin Pamoate) · HCPCS J3315
2024 spending
$11.4M
Beneficiaries
3,298
7,918 claims
Per beneficiary
$3,447
2024 ASP limit $438.88 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $11,316,962 |
| 2021 | $23,819,755 |
| 2022 | $12,310,846 |
| 2023 | $9,957,976 |
| 2024 | $11,367,888 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- [Change of the LHRH analogue in progressive castration-refractory prostate cancer].
Heidenreich A, Porres D, Epplen R, et al. · Urologe A 2012 · Randomized Controlled Trial
- Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer.
Shore ND, Sieber P, Schimke L, et al. · Urol Nurs 2013 · Comparative Study, Multicenter Study
- Metabolic consequences of gonadotropin-releasing hormone agonists vs orchiectomy: a randomized clinical study.
Østergren PB, Kistorp C, Fode M, et al. · BJU Int 2019 · Comparative Study, Randomized Controlled Trial
- Assessment of Two Formulations of Triptorelin in Chinese Patients with Endometriosis: A Phase 3, Randomized Controlled Trial.
Li X, Li H, Shi H, et al. · Adv Ther 2022 · Clinical Trial, Phase III, Multicenter Study
- Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer.
Heyns CF, Simonin MP, Grosgurin P, et al. · BJU Int 2003 · Clinical Trial, Comparative Study
- A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty.
Yu X, Cheng X, Wei H, et al. · Adv Ther 2024 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Verity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.